The levels of exosomal EDIL3 and fibronectin from breast cancer patients who underwent surgery were dramatically reduced, suggesting that EDIL3 and fibronectin in circulating EVs can also serve as treatment response markers [50,51]. The gene discussed is EDIL3; the disease is breast cancer.